Abstract: Disclosed herein are, inter alia, inhibitors of protein arginine methyltransferase 9 and pharmaceutical compositions thereof, and methods comprising the use of protein arginine methyltransferase 9 inhibitors for the treatment of a protein arginine methyltransferase 9-modulated disease or disorder, such as a hematological cancer.

Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Abstract: Information output methods and apparatuses, computer equipment and readable storage media which relate to the field of computer technology are provided. The information output method includes: detecting whether a search connection is established between a delivery terminal and a beacon device deployed by a target physical object by using a pre-cached joint beacon atlas bound to the target physical object, where the joint beacon atlas records a set of communication identifiers covered by a physical object; if the search connection is established between the delivery terminal and the beacon device deployed by the target physical object, outputting a corresponding time point when the search connection is in a stable state as information of a delivery resource arriving at the target physical object.

Abstract: Embodiments of this application relate to the video coding and compression field, and disclose an encoding method and apparatus, and a decoding method and apparatus, to resolve a problem that an existing split mode cannot satisfy a relatively complex texture requirement. The decoding method specifically includes: parsing a bitstream to determine a basic split mode for a current to-be-decoded picture block and a target derivation mode for a subpicture block of the current to-be-decoded picture block; splitting the current to-be-decoded picture block into N subpicture blocks in the basic split mode, where N is an integer greater than or equal to 2; deriving one derived picture block from at least two adjacent subpicture blocks in the N subpicture blocks in the target derivation mode; and decoding the derived picture block.

Abstract: The present application relates to a protein-drug conjugate, containing an antigen binding protein portion and a drug conjugate portion. The antigen binding protein portion comprises one or more antigen binding fragments, and at least two linker peptides are directly or indirectly connected to the antigen binding fragments. The two linker peptides can each independently contain a first cysteine Cys1 and a second cysteine Cys2. The drug conjugate portion is covalently bonded on Cys1. The present application further relates to a preparation method for the protein-drug conjugate, and a use for the protein-drug conjugate in preventing or treating tumors or other diseases.

Abstract: An decoding method is disclosed, including: parsing a bitstream to obtain a first flag, wherein the first flag specifies whether a current coding block is required to be partitioned; when the first flag specifies that the current coding block is required to be partitioned, parsing the bitstream to obtain a second flag, wherein the second flag specifies whether the current coding blocks is partitioned in a horizontal direction or a vertical direction; partitioning the current coding block into four first rectangular subblocks in the horizontal direction or four second rectangular subblocks in the vertical direction; and reconstructing the current coding block based on the four first rectangular subblocks or the four second rectangular subblocks.

Abstract: Provided an isolated antigen binding protein having one or more of the following properties: a. capable of binding to both human CD73 and Cynomolgus monkey CD73; b. capable of inhibiting 5?ectonucleotidase activity of CD73; c. capable of mediating CD73 internalization; d. capable of promoting T cell proliferation; e. with a relatively stable concentration in serum; and f. capable of inhibiting tumor growth and/or tumor cell proliferation. In addition, provided a method for producing the isolated antigen binding protein as well as pharmaceutical uses of the isolated antigen binding protein in preventing, alleviating and/or treating tumor.

Abstract: The present disclosure relates to a laser coupling device, which includes a plurality of laser units, configured to emit laser beams; and at least one first convex lens, arranged on optical paths of the laser beams and configured to converge the laser beam. The laser coupling device can emit laser beam with a high power.

Abstract: The present invention provides a method for improving the stability of pramipexole or its salt preparation, and further provides a pramipexole hydrochloride oral liquid with excellent stability and oral absorption effect. The pramipexole hydrochloride oral liquid of the present invention is prepared through a simple process, and shows bioequivalence with the tablet containing pramipexole hydrochloride. The invention perfectly realizes multi-dose administration of pramipexole hydrochloride and improves the compliance and accessibility of medication for patients.

Abstract: Disclosed is a binding protein having at least two protein functional regions, the binding protein comprising a protein functional region A and a protein functional region B; the protein functional region A and the protein functional region B target different antigens or epitopes, the protein functional region A is a Fab or a scFv structure, the protein functional region B is a VH structure, and there are one or more of each of the protein functional region A and the protein functional region B. A multi-specific binding protein has a smaller molecular weight, fewer polypeptide chains, and a simpler structure. By means of different structure types, relative positions, binding valence and other parameters, the functional activities for different targets can be adjusted, and then different combinations of activities can be designed so as to meet the needs of different dose combinations of clinical combinations.

Abstract: The present invention provides a binding protein and use thereof, wherein the binding protein comprises a first protein functional region binding to a targeting moiety of an antigen on a target cell, and a second protein functional region binding to an effector moiety of an antigen on an immune effector cell; and the binding protein is selected from the following structure: the first protein functional region is of a Fab structure, the second protein functional region is of a VH structure or a Fab structure, and the first protein functional region and the second protein functional region are arranged sequentially from the N-terminus to the C-terminus of the binding protein. The binding protein can bring the immune effector cell and the specific target cell together, efficiently and selectively activate the immune effector cell in a microenvironment of the specific target cell, further enhance immune responses, and reduce toxic and side effects caused by non-specific activation of peripheral immune cells.

Abstract: Provided is a binding protein, which comprises a protein functional region A and a protein functional region B, both of which target different antigens or different epitopes of antigens. The protein functional region A is Fab; the protein functional region B is VH; and the binding protein also comprises an Fc homodimer. There are two of both the protein functional region A and the protein functional region B. The binding protein has a left-right symmetrical structure. The binding protein consists of the protein functional region A, the protein functional region B and Fc in sequence from the N-terminus to the C-terminus, wherein the protein functional region A and the protein functional region B are connected by means of L1, and the protein functional region B is connected to the Fc by means of L2. The binding protein has a relatively small molecular mass, few polypeptide chains and a simpler structure. The protein has a versatile structure and may be applied to a variety of different target combinations.

Abstract: An encoding method with multiple image block division manners is disclosed, including: determining a division manner and a division direction of an image block; dividing the image block to obtain image subblocks sequentially arranged horizontally or vertically; determining whether the image subblocks need subdivision, and if subdivision is not needed, predicting the encoding object in the frame according to the image subblocks, to obtain residual data; performing transformation, quantization, and entropy encoding for the residual data so as to obtain coded residual data; and writing the division manner of the image block, the division direction of the image block, an identifier indicating whether the image subblocks need subdivision, and the coded residual data into a bitstream. By applying the encoding method, better prediction accuracy can be achieved when the image block presents a small change of pixel value in the horizontal or vertical direction.

Abstract: A method and device for coding and decoding are disclosed. The method includes: dividing a picture to be encoded into several slices, each containing macroblocks continuous in a designated scanning sequence in the picture; dividing slices in the picture into one or more slice sets according to attribute information of the slices, each slice set containing one or more slices; and encoding the slices in the slice sets according to slice and slice set division information to get a coded bit stream of the picture. The decoding method includes: obtaining slice and slice set division information from a bit stream to be decoded and decoding the bit stream according to the obtained slice and slice set division information. The invention improves the performance of video transmission effectively and realizes region based coding. The implementation of coding and decoding is simple and the complexity of coding and decoding systems is reduced.

Abstract: The present invention discloses a 4-1BB-binding protein and use thereof. The 4-1BB-binding protein comprises a heavy chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises a sequence as set forth in SEQ ID NO: 15 or a variant 1 thereof, or SEQ ID NO: 16; the HCDR2 comprises a sequence selected from SEQ ID NO: 60 or a variant 2 thereof, and SEQ ID NO: 50 or a variant 4 thereof; the HCDR3 comprises a sequence as set forth in SEQ ID NO: 103 or a variant 3 thereof, SEQ ID NO: 333 or a variant 5 thereof, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 116, SEQ ID NO: 326, SEQ ID NO: 331, SEQ ID NO: 334 or SEQ ID NO: 96. The 4-1BB-binding protein of the present invention is a fully human antibody having the binding activity to human 4-1BB and cynomolgus monkey 4-1BB. Some 4-1BB-binding proteins are only half the size of conventional IgG antibodies; they can be well used for bispecific antibodies.

Abstract: A Fc-CD80 fusion protein has a CD80 extracellular domain (ECD) linked to a C-terminal of an immunoglobulin Fc domain. The Fc-CD80 fusion protein can be used for the preparation of a conjugate, the conjugate including the Fc-CD80 fusion protein as a first component, and a second component containing a second effector molecule, the second component being located at an N-terminal of the first component. In addition, a conjugate including the Fc-CD80 fusion protein, a pharmaceutical composition including the Fc-CD80 fusion protein and/or the conjugate are effective for the treatment or prevention of cancerous diseases in individuals.

Abstract: Provided are a bispecific antibody and use thereof. The bispecific antibody comprises a B7-H4-targeting antigen-binding domain and a 4-1BB-targeting antigen-binding domain. The bispecific antibody has one or two or three sites for binding to 4-1BB, along with a novel fully human B7-H4 antibody. The bispecific antibody specifically binds to tumor cells by targeting B7-H4, reducing toxicity induced by 4-1BB activation. In addition, the bispecific antibody of the present invention comprises a human Fc fragment, and thus retains the binding of Fc to FcRn and has a longer half-life.